{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:52:30Z","timestamp":1790013150489,"version":"4.0.1"},"reference-count":51,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"unspecified","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2017897"],"award-info":[{"award-number":["2017897"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Diamedica Therapeutics"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,11,14]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pre-eclampsia and fetal growth restriction are leading causes of perinatal morbidity and mortality. A therapy that enhances maternal vascular function and promotes vasodilation to increase placental perfusion could treat both conditions.<\/jats:p>\n                    <jats:p>Tissue kallikrein-1 is an endogenous enzyme that releases bradykinin to activate the bradykinin 2 receptor on endothelial cells. This induces potent vasodilation and pro-angiogenic, anti-oxidant and anti-inflammatory effects.<\/jats:p>\n                    <jats:p>DM199 is a recombinant form of tissue kallikrein which can be administered intravenously or subcutaneously. Clinical trials in non-pregnant populations have demonstrated its safety. Being a protein, it is unlikely to cross the placenta. This protocol describes an early-phase trial for DM199 for pre-eclampsia and fetal growth restriction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This phase IB\/IIA open-label trial at Tygerberg Hospital, Western Cape Province, South Africa, will determine the safety and effective dose of DM199 for pre-eclampsia and\/or fetal growth restriction. The trial consists of two parts. Part 1 will be an ascending dose finding study, treating women with pre-eclampsia and severe hypertension who are for planned birth within 72 hours. This will search for doses that safely lower blood pressure (n=3\/dose, recruiting up to 42 participants). Part 2 is a safety and efficacy study of three cohorts of pregnant women (n=30\/cohort): (1) with pre-eclampsia and severe hypertension requiring delivery within 72 hours, (2) with preterm pre-eclampsia (&lt;33\u2009weeks\u2019 gestation) undergoing expectant management and (3) with preterm fetal growth restriction. Primary outcomes will include adverse events and umbilical cord concentrations of DM199. DM199 pharmacokinetics will be described and exploratory outcomes assessed to evaluate preliminary evidence of efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The trial has ethical approval (Health Research Ethics Committee, Stellenbosch University, Protocol number M24\/04\/009) and is registered (Pan African Clinical Trial Registry, PACTR202404895013782) and approved by the South African Health Products Regulatory Authority (20240801). Data will be presented at international conferences and published in peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-104035","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:10:11Z","timestamp":1771326611000},"page":"e104035","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and potential efficacy of DM199, a tissue kallikrein-1 analogue, for treating pre-eclampsia and fetal growth restriction: study protocol for a South African, hospital-based phase I\/II open-label trial"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct01845064","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03290560","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04123613","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0406-8964","authenticated-orcid":false,"given":"Catherine Anne","family":"Cluver","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Stellenbosch University, Tygerberg Hospital, Cape Town, South Africa"},{"name":"Translational Obstetrics Group, University of Melbourne, Heidelberg, Victoria, Australia"},{"name":"Mercy Perinatal, Mercy Hospital, Heidelberg, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2378-1727","authenticated-orcid":false,"given":"Jacquline","family":"Thake","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Stellenbosch University, Tygerberg Hospital, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasleem","family":"Hassim","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Stellenbosch University, Tygerberg Hospital, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1014-7068","authenticated-orcid":false,"given":"Anriette","family":"van Greunen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Stellenbosch University, Tygerberg Hospital, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5747-1714","authenticated-orcid":false,"given":"Samantha","family":"Budhram","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Stellenbosch University, Tygerberg Hospital, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karusha","family":"Knipe","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Stellenbosch University, Tygerberg Hospital, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1815-5150","authenticated-orcid":false,"given":"Eric","family":"Decloedt","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stellenbosch University, Cape Town, Western Cape, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6737-8225","authenticated-orcid":false,"given":"Lucy","family":"Brink","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Stellenbosch University, Tygerberg Hospital, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0350-8294","authenticated-orcid":false,"given":"Eduard","family":"Langenegger","sequence":"additional","affiliation":[{"name":"Stellenbosch University, Stellenbosch, Western Cape, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5202-9428","authenticated-orcid":false,"given":"Lina","family":"Bergman","sequence":"additional","affiliation":[{"name":"University of Gothenburg, Got\u00ebborg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9447-663X","authenticated-orcid":false,"given":"Henrik","family":"Imberg","sequence":"additional","affiliation":[{"name":"Statistiska Konsultgruppen, G\u00f6teborg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrie","family":"Bekker","sequence":"additional","affiliation":[{"name":"Stellenbosch University, Stellenbosch, Western Cape, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9075-4655","authenticated-orcid":false,"given":"Susan P","family":"Walker","sequence":"additional","affiliation":[{"name":"Translational Obstetrics Group, University of Melbourne, Heidelberg, Victoria, Australia"},{"name":"Mercy Perinatal, Mercy Hospital, Heidelberg, Victoria, Australia"},{"name":"Department of Obstetrics, Gynaecology and Newborn Health, University of Melbourne, Heidelberg, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2319-0586","authenticated-orcid":false,"given":"Stephen","family":"Tong","sequence":"additional","affiliation":[{"name":"Translational Obstetrics Group, University of Melbourne, Heidelberg, Victoria, Australia"},{"name":"Mercy Perinatal, Mercy Hospital, Heidelberg, Victoria, Australia"},{"name":"Department of Obstetrics, Gynaecology and Newborn Health, University of Melbourne, Heidelberg, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"2026010307015756000_15.12.e104035.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32335-7"},{"key":"2026010307015756000_15.12.e104035.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60686-8"},{"key":"2026010307015756000_15.12.e104035.3","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ajog.2021.11.1357","article-title":"Clinical Opinion: The diagnosis and management of suspected fetal growth restriction: an evidence-based approach","volume":"226","author":"Lees","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"2026010307015756000_15.12.e104035.4","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2015-0225-CC"},{"key":"2026010307015756000_15.12.e104035.5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.853127"},{"key":"2026010307015756000_15.12.e104035.6","doi-asserted-by":"crossref","first-page":"S1157","DOI":"10.1016\/j.ajog.2020.09.014","article-title":"Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia","volume":"226","author":"Tong","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"2026010307015756000_15.12.e104035.7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3390\/ph14030240","article-title":"Kinins and Kinin Receptors in Cardiovascular and Renal Diseases","volume":"14","author":"Girolami","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026010307015756000_15.12.e104035.8","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneph0444"},{"key":"2026010307015756000_15.12.e104035.9","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M100229200"},{"key":"2026010307015756000_15.12.e104035.10","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvn223"},{"key":"2026010307015756000_15.12.e104035.11","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109493200"},{"key":"2026010307015756000_15.12.e104035.12","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.108.182139"},{"key":"2026010307015756000_15.12.e104035.13","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.109.184549"},{"key":"2026010307015756000_15.12.e104035.14","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000142051.36244.83"},{"key":"2026010307015756000_15.12.e104035.15","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0b013e32834d54b1"},{"key":"2026010307015756000_15.12.e104035.16","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3892\/mmr.2020.11805","article-title":"Co\u2011expression of tissue kallikrein 1 and tissue inhibitor of matrix metalloproteinase 1 improves myocardial ischemia\u2011reperfusion injury by promoting angiogenesis and inhibiting oxidative stress","volume":"23","author":"Huang","year":"2021","journal-title":"Mol Med Rep"},{"key":"2026010307015756000_15.12.e104035.17","doi-asserted-by":"crossref","first-page":"24675","DOI":"10.18632\/oncotarget.5071","article-title":"Bradykinin inhibits oxidative stress-induced senescence of endothelial progenitor cells through the B2R\/AKT\/RB and B2R\/EGFR\/RB signal pathways","volume":"6","author":"Fu","year":"2015","journal-title":"Oncotarget"},{"key":"2026010307015756000_15.12.e104035.18","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2012.105"},{"key":"2026010307015756000_15.12.e104035.19","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-017-2286-0","article-title":"The Placental Barrier: the Gate and the Fate in Drug Distribution","volume":"35","author":"Tetro","year":"2018","journal-title":"Pharm Res"},{"key":"2026010307015756000_15.12.e104035.20","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2008.055277"},{"key":"2026010307015756000_15.12.e104035.21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.18203\/2349-3259.ijct20174861","article-title":"Safety, tolerability and pharmacokinetic profile of recombinant human tissue kallikrein, DM199, after intravenous and subcutaneous administration in healthy volunteers","volume":"4","author":"Alexander-Curtis","year":"2017","journal-title":"Int J Clin Trials"},{"key":"2026010307015756000_15.12.e104035.22","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/cpdd.1534","article-title":"A Phase 1C, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DM199 Administered Intravenously with a Polyvinyl Chloride Bag in Adult Healthy Subjects and Adults Recently Taking Angiotensin-Converting Enzyme Inhibitors","volume":"14","author":"Giuffre","year":"2025","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2026010307015756000_15.12.e104035.23","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1161\/STROKEAHA.124.048858","article-title":"Recombinant Human Tissue Kallikrein-1 for Treating Acute Ischemic Stroke and Preventing Recurrence","volume":"56","author":"Kasner","year":"2025","journal-title":"Stroke"},{"key":"2026010307015756000_15.12.e104035.24","doi-asserted-by":"crossref","unstructured":"Alexander-Curtis M , Pauls R , Chao J , et al . Human tissue kallikrein in the treatment of acute ischemic stroke. Ther Adv Neurol Disord 2019;12. doi:10.1177\/1756286418821918","DOI":"10.1177\/1756286418821918"},{"key":"2026010307015756000_15.12.e104035.25","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-018-0638-z"},{"key":"2026010307015756000_15.12.e104035.26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/DDDT.S76135","article-title":"Sample sizes in dosage investigational clinical trials: a systematic evaluation","volume":"9","author":"Huang","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"2026010307015756000_15.12.e104035.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.preghy.2021.09.008"},{"key":"2026010307015756000_15.12.e104035.28","doi-asserted-by":"publisher","DOI":"10.1002\/uog.20272"},{"key":"2026010307015756000_15.12.e104035.29","doi-asserted-by":"publisher","DOI":"10.1002\/uog.15884"},{"key":"2026010307015756000_15.12.e104035.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2026010307015756000_15.12.e104035.31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/pd.6047","article-title":"Development of standard definitions and grading for Maternal and Fetal Adverse Event Terminology","volume":"42","author":"Spencer","year":"2022","journal-title":"Prenat Diagn"},{"key":"2026010307015756000_15.12.e104035.32","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2019-317399"},{"key":"2026010307015756000_15.12.e104035.33","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0b013e32834d54b1"},{"key":"2026010307015756000_15.12.e104035.34","article-title":"Nitric Oxide as a Central Molecule in Hypertension: Focus on the Vasorelaxant Activity of New Nitric Oxide Donors","volume":"10","author":"da Silva","year":"2021","journal-title":"Biology (Basel)"},{"key":"2026010307015756000_15.12.e104035.35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1997.tb00513.x"},{"key":"2026010307015756000_15.12.e104035.36","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-200102000-00003"},{"key":"2026010307015756000_15.12.e104035.37","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(21)00217-8","article-title":"Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials","volume":"397","author":"Stewart","year":"2021","journal-title":"The Lancet"},{"key":"2026010307015756000_15.12.e104035.38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00404-017-4418-5","article-title":"The role of prostaglandins E1 and E2, dinoprostone, and misoprostol in cervical ripening and the induction of labor: a mechanistic approach","volume":"296","author":"Bakker","year":"2017","journal-title":"Arch Gynecol Obstet"},{"key":"2026010307015756000_15.12.e104035.39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704559"},{"key":"2026010307015756000_15.12.e104035.40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ijgo.13522","article-title":"FIGO (International Federation of Gynecology and Obstetrics) initiative on fetal growth: Best practice advice for screening, diagnosis, and management of fetal growth restriction","volume":"152","author":"Melamed","year":"2021","journal-title":"Intl J Gynecology & Obste"},{"key":"2026010307015756000_15.12.e104035.41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S2352-4642(17)30173-6","article-title":"Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial","volume":"2","author":"Sharp","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"2026010307015756000_15.12.e104035.42","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.15658"},{"key":"2026010307015756000_15.12.e104035.43","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.5323","article-title":"Maternal Sildenafil vs Placebo in Pregnant Women With Severe Early-Onset Fetal Growth Restriction: A Randomized Clinical Trial","volume":"3","author":"Pels","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026010307015756000_15.12.e104035.44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/AOG.0000000000001518","article-title":"Perinatal and Hemodynamic Evaluation of Sildenafil Citrate for Preeclampsia Treatment: A Randomized Controlled Trial","volume":"128","author":"Trapani","year":"2016","journal-title":"Obstet Gynecol"},{"key":"2026010307015756000_15.12.e104035.45","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ajog.2020.08.004","article-title":"Prospective, randomized, double-blind, placebo-controlled evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia","volume":"223","author":"Paidas","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"2026010307015756000_15.12.e104035.46","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ajog.2018.07.019","article-title":"Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial","volume":"219","author":"Cluver","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"2026010307015756000_15.12.e104035.47","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n2103","article-title":"Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial","volume":"374","author":"Cluver","year":"2021","journal-title":"BMJ"},{"key":"2026010307015756000_15.12.e104035.48","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ajog.2024.02.316","article-title":"Metformin in pregnancy and childhood neurodevelopmental outcomes: a systematic review and meta-analysis","volume":"231","author":"Gordon","year":"2024","journal-title":"Am J Obstet Gynecol"},{"key":"2026010307015756000_15.12.e104035.49","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0660"},{"key":"2026010307015756000_15.12.e104035.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2024.06.002"},{"key":"2026010307015756000_15.12.e104035.51","doi-asserted-by":"publisher","DOI":"10.1097\/01.ftd.0000184161.52573.0e"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-104035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:10:15Z","timestamp":1771326615000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-104035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":51,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,17]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjopen-2025-104035"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-104035","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}